International Multicenter Patent foRamen OVale & slagtilfælde (IMPROVE) Registry (IMPROVE)
Patent foramen ovale (PFO) is a prevalent cause of ischemic stroke and transient ischemic attack (TIA) in young patients. Its role as a cause of cerebrovascular events in the older population is more controversial because of other competing causes are more frequent in the elderly. Recent randomized controlled trials (RCTs) have shown that PFO closure is associated with a 59% relative risk reduction in the risk of recurrent ischemic stroke. As such, the number of PFO closure procedures are expected to increase substantially in the upcoming years. Real world data (RWD) informing on the medical management, the risk of stroke recurrence, incident atrial fibrillation, and other outcomes in stroke patients with PFO, with and without PFO closure, will become crucial for understanding how results from RCTs are translated into clinical practice globally.
The IMPROVE (International Multicenter Patent foRamen OVale & strokE) Registry is an observational, multicenter, international registry of men and women with an ischemic stroke or TIA. The aim is to enroll 8,800 patient-years at ≥50 sites in ≥20 countries.
The IMPROVE Registry will provide important information about the management and related outcomes of patients with ischemic stroke or TIA and PFO throughout different regions of the world and across a wide spectrum of healthcare systems.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Kontakter og lokationer
Studiesteder
-
-
Ontario
-
London, Ontario, Canada, N6A 5A5
- Heart & Brain Lab, Western University
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
The IMPROVE registry aims to include patients from Asia, Europe, Oceania, North America and Latin America. Academic, non-academic, urban and rural sites will be included. Principal investigators will be neurologists, since a confirmed diagnosis of ischemic stroke or TIA is mandatory before enrolment.
Beskrivelse
INCLUSION CRITERIA (all of the following criteria should be fulfilled)
-
Age ≥18 years
-
Ischemic stroke or TIA within 5 years and 1 year before inclusion in the registry. Patients with cerebrovascular events occurred within one year before the inclusion in the registry should be part of the prospective cohort.
-
Ischemic stroke is defined as:
- focal neurological deficit of central origin lasting ≥24 hours -except for death within 24hrs- with or without imaging confirmation of cerebral infarction; or
- focal neurological deficit of central origin lasting <24 hours with corresponding imaging evidence of cerebral infarction; or
- focal neurological deficit of central origin lasting <24 hours in patients receiving IV thrombolysis or endovascular thrombectomy with or without imaging confirmation of cerebral infarction; or
- non-focal encephalopathy lasting more than 24 hours -except for death within 24hrs- with imaging evidence of cerebral infarction; or
- acute and permanent retinal ischemia of arterial origin.
-
TIA is defined as:
- focal neurological deficit of central origin lasting <24 hours without corresponding imaging evidence of cerebral infarction in patients not receiving IV thrombolysis or endovascular thrombectomy.
-
-
Confirmed patent foramen ovale.
EXCLUSION CRITERIA:
Exclusion Criteria
- Age <18 years
- Venous stroke
- Stroke mimics
- Patients with incomplete data at 12 months after the index ischemic stroke or TIA.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: OTHER
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Sex
Female and male patients |
PFO closure after stroke or transient ischemic attack |
|
Age >60 years of age
Patients younger or oder than 6o years of age |
PFO closure after stroke or transient ischemic attack |
|
World region
Patients from different world regions: North America, Europe, Asia, Latin America |
PFO closure after stroke or transient ischemic attack |
|
Stroke vs. TIA
Index event: stroke vs. TIA |
PFO closure after stroke or transient ischemic attack |
|
Neurocardiology Teams
Patients assessed by a neurocardiology team |
PFO closure after stroke or transient ischemic attack |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Recurrent stroke
Tidsramme: Duration of follow-up (minimum of 3 months)
|
Recurrent hemorrhagic or ischemic stroke |
Duration of follow-up (minimum of 3 months)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incident atrial fibrillation
Tidsramme: Duration of follow-up (minimum of 3 months)
|
New diagnosis of atrial fibrillation after the index date |
Duration of follow-up (minimum of 3 months)
|
|
Proportion of patients undergoing PFO closure
Tidsramme: Within 12 months of the index diagnosis of PFO after the stroke or transient ischemic attack
|
Proportion of patients undergoing PFO closure |
Within 12 months of the index diagnosis of PFO after the stroke or transient ischemic attack
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Recurrent stroke or death
Tidsramme: Duration of follow-up (minimum of 3 months)
|
Recurrent hemorrhagic or ischemic stroke, or death |
Duration of follow-up (minimum of 3 months)
|
|
Recurrent stroke or myocardial infarction
Tidsramme: Duration of follow-up (minimum of 3 months)
|
Recurrent hemorrhagic or ischemic stroke, or myocardial infarction |
Duration of follow-up (minimum of 3 months)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Luciano A Sposato, MD, MBA (PI), London Health Sciences Centre, Western University (London, ON. Canada)
- Ledende efterforsker: Antonio Arauz, MD (Co-Pi), National Institute of Neurology and Neurosurgery Manuel Velasco Suárez
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Cerebrovaskulære lidelser
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Karsygdomme
- Hjerte-kar-sygdomme
- Patologiske processer
- Hjertesygdomme
- Arytmier, hjerte
- Medfødte abnormiteter
- Kardiovaskulære abnormiteter
- Hjertefejl, medfødt
- Hjerteseptumdefekter, atriel
- Hjerteseptumdefekter
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Patologiske tilstande, tegn og symptomer
- Slag
- Atrieflimren
- Foramen Ovale, Patent
- Atrieflimren
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- R-19-597
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Upon reasonable request and after the Approval of Western University Ethics Review Board
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .